ALX Oncology and Sanofi to Evaluate Evorpacept + SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma May 10, 2023
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed R/R Multiple Myeloma April 27, 2023
Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Combinatorial IO Treatment Strategies April 6, 2023
First Patient dosed in the CaMMouflage Ph 1 Trial of CB-011 for the Treatment of R/R Multiple Myeloma April 6, 2023
Elranatamab Receives FDA and EMA Filing Acceptance with Submissions based on favorable MagnetisMM-3 trial results in patients with R/R multiple myeloma February 28, 2023
UK MHRA grants full Marketing Authorization to NEXPOVIO (selinexor), Velcade, and SVd combo for previously-treated multiple myeloma patients February 22, 2023
Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Ph 1b/2 Clinical Trial to the U.S. February 22, 2023
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% vs SoC in Earlier Lines of Therapy for R/R Multiple Myeloma in Ph 3 KarMMa-3 Study February 22, 2023
42-Patient Interim Data, with 90% ORR in R/R Multiple Myeloma at NXC-201 Therapeutic Dose from Ph 1 Expansion Trial presented February 22, 2023
China NMPA Clears IND Application for Ph 1/2 Trial of FasTCAR-T GC012F for Treatment of R/R Multiple Myeloma February 22, 2023
FDA Clears IND Application for Ph 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of R/R Multiple Myeloma February 22, 2023
Kite And Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma February 8, 2023
Ph 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) meets Primary Endpoint in Patients with R/R Multiple Myeloma February 1, 2023
Data from Ph 1 UNIVERSAL Study of ALLO-715 for the Treatment of R/R Multiple Myeloma published in Nature Medicine February 1, 2023
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer January 4, 2023
FDA Approves Clinical Trial Application for BCMA CAR-T CT103A for R/R Multiple Myeloma January 4, 2023
Immix Biopharma in-licenses NXC-201, Demonstrating High CRR in Heavily Pre-Treated Multiple Myeloma (71% CR) Patients December 19, 2022
Kite And Arcellx Announce Strategic Collaboration To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma December 13, 2022
BLA submitted to U.S. FDA for Talquetamab for the Patients with R/R Multiple Myeloma December 12, 2022
FDA Clears IND Application for BCMA CAR-T CB-011 for the Treatment of R/R Multiple Myeloma November 30, 2022
FAILED TRIAL: Ph 3 DREAMM-3 trial of Blenrep (belantamab mafodotin) in patients with RRMM did not meet primary endpoint of progression-free survival (PFS) November 16, 2022
